GLRX3, a novel cancer stem cell-related secretory biomarker of pancreatic ductal adenocarcinoma

BMC Cancer

Table 2 Multivariate Cox-proportional hazard analysis for the contribution of clinical factors to DFS, PFS, and OS

	Univariate		Multivariate
	Hazard ratio (95% CI)	p value	Hazard ratio (95% CI)	p value
A. DFS after surgery (n = 20)
High GLRX3	1.007 (1.001–1.013)	0.027	1.009 (1.002–1.016)	0.008
Older age	0.975 (0.934–1.018)	0.253	0.976 (0.933–1.022)	0.306
Male gender	0.393 (0.125–1.241)	0.111	0.274 (0.081–0.932)	0.038
Higher CA19–9	1.000 (0.999–1.000)	0.742	1.000 (0.999–1.000)	0.305
B. PFS after palliative chemotherapy (n = 47)
High GLRX3	1.001 (0.997–1.005)	0.569	1.001 (0.997–1.005)	0.569
Older age	1.014 (0.988–1.041)	0.301	1.011 (0.986–1.037)	0.379
Male gender	0.589 (0.320–1.087)	0.090	0.589 (0.320–1.087)	0.090
Higher CA19–9	1.000 (1.000–1.000)	0.361	1.000 (1.000–1.000)	0.192
C. OS after initial diagnosis (n = 60)
High GLRX3	1.001 (0.998–1.004)	0.451	1.001 (0.998–1.004)	0.619
Older age	1.013 (0.988–1.039)	0.320	1.012 (0.987–1.038)	0.347
Male gender	0.611 (0.343–1.091)	0.096	0.611 (0.343–0.932)	1.091
Higher CA19–9	1.000 (1.000–1.000)	0.313	1.000 (1.000–1.000)	0.401

Abbreviations: DFS disease-free survival, PFS progression-free survival, OS overall survival, CI confidence interval

ISSN: 1471-2407